Vivus, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic diseases. The company's primary products include PANCREAZE, a pancreatic enzyme replacement therapy for Exocrine Pancreatic Insufficiency (EPI), and Qsymia, a weight management medication. PANCREAZE addresses the needs of patients with EPI, a condition characterized by a deficiency in pancreatic enzyme production, leading to chronic diarrhea, significant weight loss, and malnutrition. Qsymia is designed to help patients manage obesity and is covered by the majority of commercial healthcare plans, offering significant savings options for both insured and cash-paying patients. Vivus operates in the healthcare and pharmaceutical markets, serving patients with chronic conditions that require long-term management. The company's business model involves the development, approval, and commercialization of its pharmaceutical products, generating revenue through product sales and insurance reimbursements.

Keywords: biopharmaceutical, chronic diseases, pancreatic enzyme, weight management, EPI, obesity, healthcare, pharmaceutical, therapy, commercialization.